Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia, Refractory, with Excess of Blasts 168Myelodysplastic Syndromes 160Leukemia 156Anemia 151Leukemia, Myeloid, Acute 144Neoplasms 124Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Leukemia, Myelomonocytic, Chronic 111Multiple Myeloma 90Myeloproliferative Disorders 89Leukemia, Lymphocytic, Chronic, B-Cell 87Lymphoma, Non-Hodgkin 76Hodgkin Disease 71Lymphoma 66Congenital Abnormalities 64Anemia, Refractory 64Venous Thromboembolism 63Thrombocytopenia 59Blast Crisis 57Leukemia, Myeloid, Chronic-Phase 56Leukemia, Myeloid, Accelerated Phase 52Lymphoma, Follicular 51Myelodysplastic-Myeloproliferative Diseases 48Anemia, Aplastic 46Primary Myelofibrosis 44Lymphoma, Mantle-Cell 44Neoplasms, Plasma Cell 43Lymphoma, Large B-Cell, Diffuse 41Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 41Burkitt Lymphoma 41

Interventions

maltodextrin 1Glutamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Vaso-Occlusive Crises × Classical hematology × Clear all
NCT01179217 2020-08-19

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

Emmaus Medical, Inc.

Phase 3 Completed
230 enrolled 19 charts 1 FDA
Classical hematology

Vaso-Occlusive Crises, Anemia, Sickle Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡